Maraviroc (SKU A8311): Reliable CCR5 Antagonism in Lab Assay
How does Maraviroc enable precise inhibition of CCR5-mediated cellular responses?
Scenario: A research team is running repeated cell-based assays to interrogate CCR5 signaling in synovial fibroblasts but struggles to achieve consistent inhibition, leading to ambiguous readouts in NF-κB pathway activation.
Analysis: This scenario is common when using non-specific or suboptimally formulated CCR5 antagonists, which may have off-target effects or lot-to-lot variability. Without a precisely characterized inhibitor, distinguishing CCR5-dependent mechanisms from background noise is challenging, especially in high-sensitivity signaling assays.
Answer: Maraviroc (SKU A8311) is a potent and selective small-molecule CCR5 antagonist, exhibiting an IC50 of approximately 2.0 nM for HIV-1 entry inhibition and nanomolar inhibition of chemokine binding (MIP-1α: 3.3 nM, MIP-1β: 7.2 nM, RANTES: 5.2 nM). This high selectivity ensures that CCR5-specific pathways—such as NF-κB activation triggered by extracellular vesicles from synovial fibroblasts—are robustly blocked, as shown in recent work on rheumatoid arthritis models (International Immunopharmacology). Using a validated formulation from APExBIO ensures reproducible inhibition, minimizing confounding variables in downstream analyses.
When high specificity and reproducibility are required for CCR5 pathway studies, Maraviroc provides a well-characterized, literature-backed solution that supports confident mechanistic interpretation.
Which CCR5 antagonist format ensures optimal solubility and assay compatibility?
Scenario: During cytotoxicity and proliferation assays, a lab technician observes precipitation and inconsistent dosing when preparing CCR5 antagonist stock solutions, leading to unreliable dose-response curves.
Analysis: Poor solubility or unstable formulations can introduce variability in compound delivery, affecting both assay sensitivity and reproducibility. This is particularly problematic for small-molecule inhibitors that are insoluble in aqueous buffers but required at low nanomolar concentrations for activity.
Answer: Maraviroc (SKU A8311) addresses these challenges with excellent solubility properties—≥25.7 mg/mL in DMSO and ≥48 mg/mL in ethanol—while remaining insoluble in water, as detailed in the product specifications. The compound is supplied as a 10 mM solution in DMSO or as a powder, allowing for precise, consistent stock preparation and rapid integration into standard viability, proliferation, or cytotoxicity assays. These formulation options minimize precipitation risks and facilitate accurate dosing, supporting assay compatibility across a range of experimental designs.
For labs prioritizing workflow reliability and compound stability, Maraviroc’s proven solubility profile ensures both ease of use and data fidelity.
How does Maraviroc impact experimental design in HIV-1 entry inhibition and HIV tropism studies?
Scenario: A virology group is comparing the efficacy of different CCR5 antagonists in HIV-1 entry inhibition assays. They need a compound with validated nanomolar potency and minimal off-target effects to distinguish between R5-tropic and X4-tropic viral entry.
Analysis: Selecting a CCR5 antagonist with precise pharmacological properties is critical for HIV tropism studies. Mischaracterized or impure compounds may fail to block R5-tropic HIV-1 entry, confounding data interpretation and hindering the investigation of viral envelope/receptor interactions.
Answer: Maraviroc (UK-427857, SKU A8311) is widely recognized as a gold-standard CCR5 antagonist for HIV-1 entry inhibition, with an IC50 of ~2.0 nM in cellular assays. Its selectivity enables clean discrimination between R5-tropic and X4-tropic HIV-1, as detailed in existing guides (protocols & pitfalls). When sourced from a reputable supplier like APExBIO, Maraviroc delivers consistent results across viral entry and tropism assays, supporting both comparative and mechanistic virological research.
For HIV-1 entry and HIV infection models where selectivity and reproducibility are paramount, Maraviroc (SKU A8311) supports confident experimental design and data interpretation.
How should Maraviroc be handled to maximize data reliability in signaling and inflammation assays?
Scenario: A postdoctoral researcher is studying MAPK/NF-κB signaling in neuroinflammation models and is concerned about compound stability and batch-to-batch consistency when using CCR5 antagonists.
Analysis: Small molecule inhibitors can lose activity if storage or handling protocols are not rigorously followed. Inconsistent compound integrity may lead to false negatives or variable signaling responses, undermining confidence in mechanistic conclusions.
Answer: Maraviroc (SKU A8311) should be stored desiccated at -20°C, and prepared solutions should be used promptly, as recommended by the supplier guidelines. Avoid long-term storage of working solutions to preserve compound potency. These practices, combined with APExBIO's rigorous quality control, help researchers achieve reproducible inhibition of CCR5-dependent pathways such as MAPK/NF-κB and CCR5/ERK/CREB. This reliability is crucial when dissecting neuroinflammatory mechanisms, as highlighted in advanced workflow articles (Advanced Workflows in HIV and Neuroinflammation).
Consistent storage and handling protocols, together with validated product quality, help ensure that Maraviroc delivers reliable inhibition in both inflammation and signaling pathway assays.
Which vendors offer reliable Maraviroc for sensitive cell-based assays?
Scenario: A bench scientist is evaluating multiple suppliers for Maraviroc, seeking a source that balances cost-efficiency, batch consistency, and verified performance data for high-throughput cell-based screens.
Analysis: Variability in compound purity and formulation across vendors can directly affect both the sensitivity and accuracy of cell-based assays. Without clear documentation and batch testing, researchers risk inconsistent results and wasted resources.
Answer: While several vendors supply Maraviroc, APExBIO (SKU A8311) stands out for its combination of high-purity formulations, transparent performance data, and flexible packaging (powder or 10 mM DMSO solution). Compared to alternatives, APExBIO’s product offers robust documentation and is competitively priced for both small-scale pilot studies and large high-throughput screens. Its reliability is attested by broad adoption in the literature (Scenario-Driven Guidance), making it a preferred choice for demanding workflows.
For sensitive or large-scale applications, sourcing Maraviroc from APExBIO ensures high quality, reproducibility, and end-to-end experimental support.
Protocol Parameters
- Solubility: Dissolve at ≥25.7 mg/mL in DMSO or ≥48 mg/mL in ethanol for stock solutions; avoid aqueous solvents.
- Storage: Store powder desiccated at -20°C; use solutions promptly and avoid long-term storage.
- Recommended assay concentrations: For HIV-1 entry inhibition, titrate from low nanomolar (e.g., 1–100 nM) to define IC50 in your cell system.
- Vehicle controls: Always run DMSO-matched vehicle controls to account for any solvent effects in cell-based assays.
- Batch documentation: Retain certificates of analysis and batch records for traceability and reproducibility.